Linkage between immunomodulation, neuroprotection and neurogenesis

Drug News and Perspectives

Volumn 22, Issue 6, 2009, Pages 301-312

  Aharoni, Rina ^a   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; NEUROTROPHIC FACTOR; STEROID; TERIFLUNOMIDE;

ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; CELL RENEWAL; CELL THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; MYELINATION; NERVE FIBER REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PROTEIN SECRETION; REMYELINIZATION; REVIEW; TISSUE REPAIR; TREATMENT PLANNING;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROGENESIS; NEUROPROTECTIVE AGENTS;

EID: 70350551949     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.6.1395253     Document Type: Review

References (136)

1. Feltkamp, T.E.W. The mystery of autoimmune diseases. In: The Decade of Autoimmunity. Shoenfeld, Y. (Ed.). Elsevier 1999, 1-5.
2. Hohlfeld, R. and Wekerle, H. Autoimmune concepts of MS as a basis for selective immunotherapy, from the pipe dreams to therapeutic pipelines. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2): 14599-14606 (Pubitemid 39346730)
3. Trapp, B.D. and Nave, K.A. Multiple sclerosis: an immune or neurodegenerative disease. Annu Rev Neurosci 2008, 31: 247-269
4. Lassmann, H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci 2008, 274(1-2): 45-47
5. Holmoy, T. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Minerva Med 2008, 99(2): 119-140 (Pubitemid 351946150)
6. Bruck, W. Evidence for primary myodegeneration in MS. Mult Scler 2008, 14(Suppl. 1) S9: 13.
7. Geurts, J.J. and Barkhof, F. Grey matter pathology in multiple sclerosis. Lancet Neurol 2008, 7(9): 841-851
8. Lassmann, H., Bruck, W. and Lucchinetti, C.F. The immunopathology of MS: an overview. Brain Pathol 2007, 17(2): 210-218
9. Villoslada, P., Moreno, B., Melero, I. et al. Immunotherapy for neurological disease. Clin Immunol 2008, 128(3): 294-305.
10. Monahan, A.J., Warren, M. and Carvey, P.M. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant 2008, 17(4): 363-372 (Pubitemid 351717339)
11. Smith, P.F. Inflammation in Parkinson's disease: an update. Curr Opin Investig Drugs 2008, 9(5): 478-484
12. Vajda, F.J.E. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002, 9(1): 4-8.
13. Lassmann, V., Gottmann, K. and Malcangio, M. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 2003, 69(5): 341-374 (Pubitemid 36645053)
14. Kalb, R. The protean action of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci 2005, 28(1): 5-11. (Pubitemid 40038796)
15. Gillespie L.N. Regulation of axonal growth and guidance by the neurotrophic family of neurotrophic factors. Clin Exp Pharmacol Physiol 2003, 30(10): 724-733
16. Cui, Q. Actions of neurotrophic factors and their signaling pathways in neuronal survival and axonal regeneration. Mol Neurobiol 2006, 33(2): 155-179 (Pubitemid 43780372)
17. Riley, C.P., Cope, T.C. and Buck, C.R. CNS neurotrophins are biologically active and expressed by multiple cell types. J Mol Histol 2004, 35(8-9): 771-783
18. Murer, M.G., Yan, Q. and Raisman-Vozari, R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's diseases and Parkinson's disease. Prog Neurobiol 2001, 63(1): 71-124. (Pubitemid 30752602)
19. Hennigan, A., O'Callaghan, E.M. and Kelly, A.M. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans 2007, 35(2): 424-427 (Pubitemid 46596521)
20. Deister, C. and Schmidt, C.E. Optimizing neurotropic factor combinations for neurite outgrowth. J Neural Eng 2006, 3(2): 172-179 (Pubitemid 43841065)
21. Hohlfeld, R., Kerschensteiner, M., Stadelmann, C., Lassmann, H. and Wekerle, H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 2006, 27(Suppl. 1): S1-7.
22. Baumann, N. and Phan-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001, 81(2): 871-927. (Pubitemid 32267079)
23. Ramon y Cajal, S. Degeneration and Regeneration of the Nervous System. Hafner: New York 1928.
24. Altman, J. and Das, G.D. Autoradiographic and histological evidence of post-natal hippocampal neurogenesis in rats. J Comp Neurol 1965, 124(3): 319-335
25. Gage, F.H. Mammalian neural stem cells. Science 2000, 287(5457): 1433-1438
26. Kempermann, G. and Gage, F.H. Neurogenesis in the adult hippocampus. Novartis Found Symp 2000, 231: 220-235
27. Alvarez-Buylla, A. and Garcia-Verdugo, J.M. Neurogenesis in adult subventrlcular zone. J Neurosci 2002, 22(3): 629-634
28. Van Praag, H., Schinder, A.F., Christie, B.R., Toni, N., Palmer, T.D. and Gage, F.H. Functional neurogenesis in adult hippocampus. Nature 2002, 415(6875): 1030-1034 (Pubitemid 34193451)
29. Iwai, M., Sato, K., Omori, N., Nagano, I., Manabe, Y., Shoji, M. and Abe, K. Three steps of neural stem cells development in gerbil dentate gyrus after transient ischemia. J. Cereb Blood Flow Metab 2002, 22(4): 411-419 (Pubitemid 34273597)
30. Chen, J., Magavi, S.S. and Macklis, J.D. Neurogenesis of corticospinal motor neurons extending spinal projections in adult mice. Proc Nat Acad Sci U S A 2004, 101(46): 16357-16362 (Pubitemid 39552849)
31. Jin, K., Sun, Y., Xie, L., Peel, A., Mao, X.O., Batteur, S. and Greenberg, D.A. Directed migration of neuronal precursors into the ischemic cerebral cortex and striatum. Mol Cell Neurosci 2003, 24(1): 171-189 (Pubitemid 37194543)
32. Aharoni, R., Eylam, R., Domev, H., Labunsky, G., Sela, M. and Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Nat Acad Sci U S A 2005, 102(52): 19045-19050 (Pubitemid 43049563)
33. Magavi, S.S., Leavitt, B.R. and Macklis, J.D. Induction of neurogenesis in the neocortex of adult mice. Nature 2000, 405(6789): 951-955
34. Picard-Riera, N., Decker, L., Delarasse, C. et al. Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice. Proc Nat Acad Sci U S A 2002, 99(20): 13211-13216
35. Aharoni, R., Arnon, R. and Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005, 25(36): 8217-8228 (Pubitemid 41292116)
36. Aktas, O., Prozorovski, T. and Zipp, F. Death ligands and autoimmune demyelination. Neuroscientist 2006, 12(4): 305-316
37. Reynolds, R., Dawson, M., Papadopoulos, D., Polito, A. Di Bello, I.C., Pham-Dinh, D. and Levine, J. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol 2002, 31(6-7): 523-526 (Pubitemid 37378263)
38. Polito, A. and Reynolds, R. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J Anat 2005, 207(6): 707-716 (Pubitemid 43019730)
39. Bruck, W., Kuhlmann, T. and Stadelmann, C. Remyelination in multiple sclerosis. J Neurol Sci 2003, 206(2): 181-185
40. Mews, I., Bergmann, M., Bunkowski, S., Gullotta, F. and Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998, 4(2): 55-62.
41. Chang, A., Tourtellotte, W.W., Rudick, R. and Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002, 346(3): 165-173 (Pubitemid 34438882)
42. Ogata, J. and Feigin, I. Schwann cells and regenerated peripheral myelin in MS: an ultrastructural study. Neurology 1975, 25(8): 713-716
43. Hammarberg, H., Lidman, O., Lundberg, C. et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 200, 20(14): 5283-5291
44. Caggiula, M., Batocchi, A.P., Frisullo, G. et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005, 62(2): 176-182 (Pubitemid 41176501)
45. Azoulay, D., Vachapova, V., Shihman, B., Miler, A. and Kami, A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 2005, 167(1-2): 215-218 (Pubitemid 41242305)
46. Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H. and Hohlfeld, R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003, 53(3): 292-304. (Pubitemid 36258633)
47. Rapalino, O., Lazarov-Spiegler, O., Agranov, E. et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998, 4(7): 814-821 (Pubitemid 28331023)
48. Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I.R., Schwartz, M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999, 5(1): 49-55. (Pubitemid 29050998)
49. Cohen, I.R. and Schwartz, M. Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol 1999, 100(1-2): 111-114 (Pubitemid 30038244)
50. Villoslada, P. and Genain, C.P. Role of nerve growth factor and other trophic factors in brain inflammation. Prog Brain Res 2004, 146: 404-414 (Pubitemid 37541396)
51. Muhallab, S., Lundberg, C., Gielen, A.W., Lidman, O., Svenningsson, A., Piehl, F. and Olsson, T. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol 2002, 55(3): 264-273
52. Aharoni, R., Kayhan, B., Eilam, R., Sela, M. and Arnon, R. Clatiramer acetate specific T- cells in the brain express TH2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003, 100(24): 14157-14162
53. Wolf, S.D., Dittel, B.N., Hardardottir, F. and Janeway, C.A., Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996, 184(6): 2271-2278 (Pubitemid 27023727)
54. Asakura, K. and Rodriguez, M. A unique population of circulating autoantibodies promotes central nervous system remyelination. Mult Scler 1998, 4(3), 217-221 (Pubitemid 28410054)
55. Ziemssen, T. and Ziemssen, F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 2005, 4(7): 460-467 (Pubitemid 41219325)
56. Pogacic, V. and Herrling, P. List of drugs in development for neurodegenerative diseases. Neurodegener Dis 2007, 4(6): 443-486
57. Schwab, M.E. Nogo and axon regeneration. Curr Opin Neurobiol 2004 14(1): 118-124
58. Karnezis, T., Mandemakers, W., McQualter, J.L. et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004, 7(7): 736-744 (Pubitemid 38859058)
59. Satoh, J., Onoue, H., Arima, K. and Yamamura, T. Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J Neuropathol Exp Neurol 2005, 64(2): 129-138 (Pubitemid 40349311)
60. Wong, E.V., David, S., Jacob, M.H. and Jay, D.G. Inactivation of myelin-associated glycoprotein enhances optic nerve regeneration. J Neurosci 2003, 23(8): 3112-3117 (Pubitemid 36531951)
61. Wang, K.C., Koprivica, V., Kim, J.A., Sivasankaran, R., Guo, Y., Neve, R.L. and He, Z. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417(6892): 941-944 (Pubitemid 34716869)
62. Schweigreiter, R., Walmsley, A.R., Niederöst, B. et al. Versican V2 and the central inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent pathways that converge at RhoA. Mol Cell Neurosci 2004, 27(2): 163-174 (Pubitemid 39370098)
63. Moreau-Fauvarque, C., Kumanogoh, A., Camand, E. et al. The transmembrane semaphore Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J Neurosci 2003, 23(27): 9229-9239 (Pubitemid 37243824)
64. Rudick, R.A., Mi, S. and Sandrock, A.W. Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Exp Opin Biol Ther 2008, 8(10): 1561-1570
65. Waxman, S.G. Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis. Trends Mol Med 2006, 12(5): 192-195
66. Bechtold, D.A., Kapoor, R. and Smith, K.J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004, 55(5): 607-616 (Pubitemid 38544320)
67. Kapoor, R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 2008, 274(1): 54-56
68. Hisahara, S., Okano, H. and Miura, M. Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination. Neurosci Res 2003, 46(4): 387-397 (Pubitemid 36842790)
69. Lubetzki, C., Williams, A. and Stankoff, B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol 2005, 18(3): 237-244 (Pubitemid 40813749)
70. Black, J.A., Liu, S., Carrithers, M., Carrithers, L.M. and Waxman, S.G. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of Phenytoin and carbamazepine. Ann Neurol 2007, 62(1): 21-33. (Pubitemid 47235277)
71. Loeb, J.A. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007, 68(Suppl. 3): S38-42.
72. Hommer, B. and Hartung, H.P. Towards the development of rational therapies in multiple sclerosis: what is on the horizon. Ann Neurol 2007, 62(4): 314-326
73. Kumar, S., Biancotti, J.C., Yamaguchi, M. and de Vellis, J. Combination of growth factors enhances remyelination in a cuprizone- induced demyelination mouse model. Neurochem Res 2007, 32(4-5): 783-797 (Pubitemid 46481308)
74. Dubois-Daicq M. and Murray, K. Why are growth factors important in oligodendrocyte physiology? Pathol Biol 2000. 48(1): 80-86
75. Stankoff, B., Aigrot, M.S., Noël, F., Wattilliaux, A., Zalc, B. and Lubetzki, C. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 2002, 22(21): 9221-9227
76. Linker, R.A., Mäurer, M., Gaupp, S. et al. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002, 8(6): 620-624 (Pubitemid 34633441)
77. Cai, D., Shen, Y., De Bellard, M., Tang, S. and Filbin, MT. Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism. Neuron 1999, 22(1): 89-101. (Pubitemid 29070096)
78. Butzkueven, H., Zhang, J.G., Soilu-Hanninen, M. et al. LIF receptor signaling limits immune- mediated demyelination by enhancing oligodendrocyte survival. Nat Med 2002, 8(6): 613-619 (Pubitemid 34633440)
79. Viehover, A., Miller, R.H., Park, S.K., Fischbach, G. and Vartanian, T. Neuregulin: an oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev Neurosci 2001, 23(4-5): 377-386 (Pubitemid 34045232)
80. Raabe, T.D., Suy, S., Welcher, A. and DeVries, G.H. Effect of neu differentiation factor isoforms on neonatal oligodendrocyte function. J Neurosci Res 1997, 50(5): 755-768 (Pubitemid 27518272)
81. Magy, L., Mertens, C., Avellana-Adalid, V. et al. Inducible expression of FGF2 by a rat oligodendrocyte precursor cell line promotes CNS myelination in vitro. Exp Neurol 2003, 184(2): 912-922
82. Butt, A.M. and Dinsdale, J. Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp Neurol 2005, 192(1): 125-133 (Pubitemid 40208545)
83. Mason, J.L., Jones, J.J., Taniike, M., Morell, P., Suzuki, K. and Matsushima, G.K. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 2000, 61(3): 251-262 (Pubitemid 30620056)
84. Frank, J.A., Richert, N., Lewis, B. et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 2002, 8(1): 24-29 (Pubitemid 34193024)
85. Calabresi, P.A., Fields, N.S., Maloni, H.W. et al. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology 1998, 51(1): 289-292
86. Wiendl, H. and Hohlfeld, R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002, 16(3): 183-200. (Pubitemid 34852318)
87. Hess, D.C. and Borlongan C.C. Stem cells and neurological diseases. Cell Prolif 2008, 41(1): 94-114.
88. Rosser, A.E., Zietlow, R. and Dunnett, S.B. Stem cell transplantation for neurodegenerative diseases. Curr Opin Neurol 2007, 20(6): 688-692 (Pubitemid 350085011)
89. Daniela, F., Vescovi, A.L. and Bottai, D. The stem cells as potential treatment for myodegeneration. Methods Mol Biol 2007, 399: 199-213.
90. McKay, R. and Kittappa, R. Will stem cell biology generate new therapies for Parkinson's disease? Neuron 2008, 58(5): 659-661
91. Chen, C.P., Kiel, M.E., Sadowski, D. and Mckinnon, R.D. From stem cells to oligodendrocytes: prospects for brain therapy. Stem Cells Rev 2007, 3(4): 280-288
92. Pluchino, S., Quattrini, A., Brambilla, E. et al. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003, 422(6933): 688-694 (Pubitemid 36514101)
93. Einstein, O., Grigoriadis. N., Mizrachi-Kol, R. et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp Neurol 2006, 198(2): 275-284
94. Einstein, O., Fainstein, N., Vaknin, I. et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 2007, 61(3): 209-218 (Pubitemid 46557345)
95. Karussis, D., Kassis, I., Kurkalli, B. and Slavin, S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008, 265(1-2): 131-135
96. Sarig, R., Baruchi, Z., Fuchs, O., Nudel, U. and Yaffe, D. Regeneration and transdifferentiation potential of muscle-derived stem cells propagated as myospheres. Stem Cells 2006, 24(7): 1769-1778 (Pubitemid 44474190)
97. Lassmann, H. Stem cell and progenitor cell transplantation in multiple sclerosis: the discrepancy between neurobiologicol attraction and clinical feasibility. J Neurol Sci 2005, 233(1-2): 83-86 (Pubitemid 40804820)
98. Hommes, O.R. Can we pass from the experimental to clinical phase in MS stem cell research? J Neurol Sci 2008, 265(1-2): 136-139
99. Fassas, A. and Mancardi, GL. Autologous hemopoietic stem cell transplantation for multiple sclerosis: Is it worthwhile? Autoimmunity 2008, Advance publication.
100. Fagius, J., Lundgren, J. and Oberg, G. Early highly aggressive MS successfully treated by heamatopoietic stem cell transplantation. Mult Scler 2009, 15(2): 229-237
101. Virley, D.J. Developing theraputics for the treatment of multiple sclerosis. J Am Soc Exp NeuroRx 2005, 2(4): 638-649
102. Pilz, C., Wipfler, P., Ladurner, G. and Kraus, J. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Drug Discov Today 2008, 13(23-24): 1013-1025
103. Comi, G., Pulizzi, A., Rovaris, M. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double- blind, placebo-controlled phase IIb study. Lancet 2008, 371(9630): 2085-2092 (Pubitemid 351842581)
104. Johnson, K.P., Knobler, R.L., Greenstein, J.L. et al. Recombinant beta interferon treatment of relapsing-remitting multiple sclerosis pilot study results. Neurology 1990, 40(1): 261.
105. Jacobs, L.D., Cookfair, D.L., Rudick, R.A. et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaboration Group (MSCRG). Ann Neurol 1996, 39(3): 285-294
106. PRIM (Prevention of relapses and disability by Interferon beta-1a subsequently in multiple sclerosis) study group. Randomized, double blind, placebo controlled study of Interferon beta-1a in relapsing-remitting multiple sclerosis: Chemical results. Lancet 1998, 352(9139): 1498-1504
107. Yong, V.W. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002, 59(6): 802-808
108. Kieseier, B.C. and Hartung, H.P. Interferon- beta and neuroprotection in multiple sclerosis - facts, hopes and phantasies. Exp Neurol 2007, 203(1): 1-4. (Pubitemid 44830028)
109. Teitelbaum, D., Meshorer, M., Hirshfeld, T., Sela, M. and Arnon R. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1971, 1(4): 242-248
110. Wolinsky, J.S. The use of glatiramer acetate in the treatment of multiple sclerosis. Adv Neurol 2006, 98, 273-292
111. Fridkis-Hareli, M., Teitelbaum, D., Gurevich, E. et al. Direct binding of myelin basic protein and synthetic copolymer 1 class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci U S A 1994, 91(11): 4872-4876
112. Aharoni, R., Teitelbaum, D., Arnon, R. and Sela, M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A 1999, 96(2): 634-639
113. Aharoni, R., Teitelbaum, D., Sela, M. and Arnon, R. Copolymer 1 induces T cells of the T helper type 2 that cross react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1997, 94(20): 10821-10826 (Pubitemid 27430819)
114. Arnon, R. and Aharoni, R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2): 14593-14598 (Pubitemid 39346729)
115. Schrempf, W. and Ziemssen, T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007, 6(7): 469-475 (Pubitemid 47069973)
116. Weber, M.S., Hohlfeld, R. and Zamvil, S.S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 2007, 4(4): 647-653 (Pubitemid 47499292)
117. Tubridy, N., Behan, P.O., Capildeo, R. et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999, 53(3): 466-472
118. Sorensen, P.S., Fazekas, F. and Lee, M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002, 9(6): 557-563 (Pubitemid 36961280)
119. Kappos, L., Antel, J., Comi, G. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355(11): 1124-1140 (Pubitemid 44394919)
120. Biernacki, K., Antel, J.P., Blain, M., Narayanan, S., Arnold, D.L. and Prat, A. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005, 62(4): 563-568
121. Malik, O., Compston, D.A. and Scolding, N.J. Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro. J Neuroimmunol 1998, 86(2): 155-162 (Pubitemid 28305357)
122. Sättler, M.B., Demmer, I., Williams, S.K. et al. Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 2006, 201(1): 172-181 (Pubitemid 44240424)
123. Maier, K., Kuhnert, A.V., Taheri, N. et al. Effects of glatiramer acetate and interferon- beta on myodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006 169(4): 1353-1364 (Pubitemid 351194369)
124. Rudick, R.A., Fisher, E., Lee, J.C., Simon, J. and Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999 53(8): 1698-1704
125. Narayanan, S., De Stefano, N., Francis, G.S. et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta- 1b. J Neurol 2001, 248(11): 979-986
126. Parry, A., Clare, S., Jenkinson, M., Smith, S., Palace, J. and Matthews, P.M. MRI brain TI relaxation time changes in MS patients increase over time in both the white matter and the cortex. J Neuroimaging 2003, 13(3): 234-239 (Pubitemid 36775944)
127. Kipnis, J., Yoles, E., Porat, Z. et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000, 97(13): 7446-7451 (Pubitemid 30431483)
128. Ziemssen, T., Kumpfel, T., Kinkert, W.E.F., Neuhaus, O. and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002, 125(Pt 11): 2381-2391 (Pubitemid 35303499)
129. Gilgun-Sherki, Y., Panet, H., Holdengreber, V., Mosberg-Galiti, R. and Offen, D. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic- induced experimental autoimmune encephalomyelitis. Neurosci Res 2003 47(2): 201-207 (Pubitemid 37152456)
130. Aharoni, R., Herschkovitz, A., Eilam, R., Blumberg-Hazan, M., Sela, M., Bruck, W. and Arnon R. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008, 105(32): 11358-11363
131. Filippi, M., Rovaris, M., Rocca, M.A. and the European/Canadian Glatiramer Acetate Study Group. Glatiramer Acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001, 57(4): 731-733
132. Khan, O., Shen, Y., Caon, C. et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing- remitting multiple sclerosis. Mult Scler 2005, 11(6): 646-651 (Pubitemid 41685134)
133. Ford, C.C., Johnson, K.P., Lisak, R.P., Panitch, H.S., Shifroni, G., Wolinsky, J.S. and the Copaxone Study Group. A prospective open- labled study of glatiramer acetate: over a decade of continuous use in multiple sclerosos patients. Mult Scler 2006, 12(3): 309-320
134. Schori, H., Kipnis, J., Yoles, E. WoldeMussie, E., Ruiz, G., Wheeler, L.A. and Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implication for glaucoma. Proc. Natl Acad Sci U S A 2001, 98(6): 3398-3403 (Pubitemid 32220857)
135. Benner, E.J., Mosley, R.I., Destache, C.J. et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2004, 101(25): 9435-9440 (Pubitemid 38812892)
136. Angelov, D.N., Waibel, S., Guntinas-Lichius, O. et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2004, 101(44): 15823-15828